The COVID-19 vaccine from Dr. Peter Hotez approved for use in Indonesia

When we last talked to Dr. Peter Hotez — dean of the National School of Tropical Medicine at Baylor College of Medicine and co-director of the Center for Vaccine Development at Texas Children’s Hospital — said a version of his team’s Corbevax vaccine is about to be released. find your way to Indonesia.

IndoVac, as the new version is called, was on the cusp of approval, which Hotez said was important for Muslim-majority countries as it was the first halal vaccine. This week, that news became official, as the vaccine was approved for emergency clearance in Indonesia as a primary vaccine for adults.

By Hotez’s count, Corbevax had made its way to 80 million people in India at that time, including 70 million adolescents. The hope is that IndoVac will replicate the India success of the Corbevax in Indonesia.

Dr. PETER HOTEZ DISCUSSES COVID-19 AS SUMMER FALLS IN 2022

The plan, Hotez said, was to produce 20 million doses of IndoVac this year and 100 million by 2024. The recombinant protein-based COVID-19 vaccine was created in Houston by a team led by Hotez and Dr. Maria Elena Bottazzi.

Hotez maintains the best approach to protect the world from COVID-19 by vaccinating all countries.

“Access to vaccines in the developing world is critical to the eradication of this virus,” he said.

Bottazzi, co-director of the Texas Children’s Hospital Center for Vaccine Development and associate dean of the National School of Tropical Medicine at Baylor, added: “The need for a safe, effective, low-cost vaccine for middle- to low-income countries is central to the global fight against the COVID-19 pandemic Without widespread inoculation of populations in the developing world, which must contain safe, effective booster doses, additional variants will emerge, which will further advance the progress currently made by currently available vaccines in the United States. States and other western countries, is hindered.

IndoVac required a different approach than the group’s Corbevax vaccine. No animal cells or products are used in the production.

[email protected]

Add a Comment

Your email address will not be published.